NDTVCenter·
This US Biopharma Stock Crashes Over 55% After Lupus Drug Trial Fails To Meet Goals
Alumis shares tumbled as much as 56% after the opening bell to $9.59 per share.
Read at NDTV →
Business · 1 sources covering this
This US Biopharma Stock Crashes Over 55% After Lupus Drug Trial Fails To Meet Goals
Alumis shares tumbled as much as 56% after the opening bell to $9.59 per share.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://hindustansphere.com/embed/cluster/f08769ee1275b7ca7eeda62d1c9a23d25d5ff55d" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="This US Biopharma Stock Crashes Over 55% After Lupus Drug Trial Fails To Meet Goals"></iframe>
